CONTROL OF THE ENVIRONMENTAL IMPACT OF LFB’S ACTIVITIES
LFB has taken concrete action to control the environmental impact of its activities by implementing various policies in this area.
A policy was implemented in 2011 to reduce the quantity of packaging used to transport LFB’s medicinal products. This has allowed LFB to avoid generating several tonnes of packaging each year through the use of dedicated refrigerated trucks.
LFB employees are made aware of Corporate Social Responsibility (CSR) issues through a series of videos, which summarise the actions taken at LFB and the results obtained.
LFB has also implemented a Business Travel Plan for its employees’ home-work commuting. Notably, it introduced a new connected carpooling application, in addition to the carpooling measures already in place. In order to reduce the second source of greenhouse gas emissions at LFB, national and international business travel has been limited and all meeting rooms at LFB sites have been equipped with videoconferencing.
The lockdown imposed by the Covid-19 pandemic has largely contributed to reducing the environmental impact, since teleworking has been generalised and extended to all job functions that allow it. The deployment of software and applications supporting remote meetings has been accelerated.
In order to reduce its environmental impact, paper consumption within LFB has been controlled since 2013, and the number of printers/copiers has been reduced, by replacing them with “all-in-one” fax machines. The paper used at LFB is produced from wood from responsibly managed, FSC (Forest Stewardship Council) labelled forests. A life cycle analysis (LCA) was carried out and showed that the recycling and destruction of paper used by LFB are meet the requirements of the European Ecolabel.
For LFB’s customers, a health web portal has been developed and made available to public and private health establishments, to facilitate order processing and follow-up, with electronic paperless order forms.
REDUCED ENVIRONMENTAL IMPACT OF INDUSTRIAL OPERATIONS
In the area of its industrial operations, LFB has undertaken actions to reduce the energy and water consumption and waste.
Water is an important resource used in the manufacturing of LFB’s medicinal products. The basic effluents generated in the production processes are treated and neutralised with a technology using CO2. This technology, which has been in place since 2016 at the two main French bioproduction sites, is safer, more economically efficient and less polluting for the environment.
The recycling rate of waste (hazardous and non-hazardous) doubled in 2019, from 25% to 59.9% of waste recycled in 2019. Direct CO2 emissions from LFB’s sites decreased by 7% between 2018 and 2019 (source: LFB’s 2019 carbon footprint). This reduction was necessary in order to meet the objective set by the LEEM (French Union of Pharmaceutical Companies) of carbon neutrality for pharmaceutical industries by 2040.
Today, 100% of the electrical energy consumed by LFB at these sites in France is renewable and of French origin.